Comparable in vivo efficacy of CD28/B7, ICOS/GL50, and ICOS/GL50B costimulatory pathways in murine tumor models: IFNγ-dependent enhancement of CTL priming, effector functions, and tumor specific memory CTL

Cellular Immunology

Volumn 225, Issue 1, 2003, Pages 53-63

  Zuberek, Krystyna ^a   Ling, Vincent ^a   Wu, Paul ^a   Ma, Hak Ling ^a   Leonard, John P ^a   Collins, Mary ^a   Dunussi Joannopoulos, Kyriaki ^a  

^a PFIZER INC   (United States)

Author keywords

CD28 B7 and ICOS GL50 costimulation; Tumor immunity

Indexed keywords

ANTINEOPLASTIC AGENT; B7 ANTIGEN; CD28 ANTIGEN; CD86 ANTIGEN; GAMMA INTERFERON; HYBRID PROTEIN; IMMUNOGLOBULIN G; INDUCIBLE COSTIMULATOR PROTEIN; INTERLEUKIN 10; PROTEIN; PROTEIN GL50; TUMOR VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; FIBROSARCOMA; IN VIVO STUDY; MELANOMA; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TUMOR IMMUNITY;

MURINAE;

EID: 0345414165     PISSN: 00088749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cellimm.2003.09.002     Document Type: Article

References (42)

1. + T cell responses: the alternative approaches. Annu. Rev. Immunol. 15:1997;297-322.
2. Lenschow D.J., Walunas T.L., Bluestone J.A. CD28/B7 system of T cell costimulation. Annu. Rev. Immunol. 14:1996;233-258.
3. Robbins P.F., Kawakami Y. Human tumor antigens recognized by T cells. Curr. Opin. Immunol. 5:1996;628-636.
4. Appleman L.J., Boussiotis V.A. T cell anergy and costimulation. Immunol. Rev. 192:2003;161-180.
5. Carreno B.M., Collins M. The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Annu. Rev. Immunol. 20:2002;29-53.
6. Chambers C.A. The expanding world of co-stimulation: the two-signal model revisited. Trends Immunol. 22:2001;217-223.
7. Hutloff A., Dittrich A.M., Beier K.C.et al. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature. 397:1999;263-266.
8. Swallow M.M., Wallin J.J., Sha W.C. B7h, a novel costimulatory homolog of B7.1 and B7.2, is induced by TNFalpha. Immunity. 11:1999;423-432.
9. Mages H.W., Hutloff A., Heuck C.et al. Molecular cloning and characterization of murine ICOS and identification of B7h as ICOS ligand. Eur. J. Immunol. 30:2000;1040-1047.
10. Wang S., Zhu G., Chapoval A.I.et al. Costimulation of T cells by B7-H2, a B7-like molecule that binds ICOS. Blood. 96:2000;2808-2813.
11. Yoshinaga S.K., Whoriskey J.S., Khare S.D.et al. T-cell co-stimulation through B7RP-1 and ICOS. Nature. 402:1999;827-832.
12. Brodie D., Collins A.V., Iaboni A.et al. LICOS, a primordial costimulatory ligand? Curr. Biol. 10:2000;333-336.
13. Ling V., Wu P.W., Finnerty H.F.et al. Cutting edge: identification of GL50, a novel B7-like protein that functionally binds to ICOS receptor. J. Immunol. 164:2000;1653-1657.
14. Ling V., Wu P.W., Miyashiro J.S.et al. Differential expression of inducible costimulator-ligand splice variants: lymphoid regulation of mouse GL50-B and human GL50 molecules. J. Immunol. 166:2001;7300-7308.
15. + T cells. Proc. Natl. Acad. Sci. USA. 99:2002;6198-6203.
16. Nguyen L.T., Radhakrishnan S., Ciric B.et al. Cross-linking the B7 family molecule B7-DC directly activates immune functions of dendritic cells. J. Exp. Med. 196:2002;1393-1398.
17. Gonzalo J.A., Delaney T., Corcoran J.et al. Cutting edge: the related molecules CD28 and inducible costimulator deliver both unique and complementary signals required for optimal T cell activation. J. Immunol. 166:2001;1-5.
18. Coyle A.J., Lehar S., Lloyd C.et al. The CD28-related molecule ICOS is required for effective T cell-dependent immune responses. Immunity. 13:2000;95-105.
19. Witsch E.J., Peiser M., Hutloff A.et al. ICOS and CD28 reversely regulate IL-10 on re-activation of human effector T cells with mature dendritic cells. Eur. J. Immunol. 32:2002;2680-2686.
20. Coyle A.J., Gutierrez-Ramos J.C. The expanding B7 superfamily: increasing complexity in costimulatory signals regulating T cell function. Nat. Immunol. 2:2001;203-209.
21. Beier K.C., Hutloff A., Dittrich A.M.et al. Induction, binding specificity and function of human ICOS. Eur. J. Immunol. 30:2000;3707-3717.
22. + T cells. J. Immunol. 165:2000;5035-5040.
23. Ogasawara K., Yoshinaga S.K., Lanier L.L. Inducible costimulator costimulates cytotoxic activity and IFN-gamma production in activated murine NK cells. J. Immunol. 169:2002;3676-3685.
24. Wallin J.J., Liang L., Bakardjiev A.et al. Enhancement of CD8+ T cell responses by ICOS/B7h costimulation. J. Immunol. 167:2001;132-139.
25. Liu X., Bai X.F., Wen J.et al. B7H costimulates clonal expansion of, and cognate destruction of tumor cells by, CD8(+) T lymphocytes in vivo. J. Exp. Med. 194:2001;1339-1348.
26. DeLeo A.B., Shiku H., Takahashi T.et al. Cell surface antigens of chemically induced sarcomas of the mouse. I. Murine leukemia virus-related antigens and alloantigens on cultured fibroblasts and sarcoma cells: description of a unique antigen on BALB/c Meth A sarcoma. J. Exp. Med. 146:1977;720-734.
27. Poste G., Doll J., Hart I.R.et al. In vitro selection of murine B16 melanoma variants with enhanced tissue-invasive properties. Cancer Res. 40:1980;1636-1644.
28. Sturmhoefel K., Lee K., Gray G.S.et al. Potent activity of soluble B7-IgG fusion proteins in therapy of established tumors and as vaccine adjuvant. Cancer Res. 59:1999;4964-4972.
29. Bennett F., Luxenberg D., Ling V.et al. Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses. J. Immunol. 170:2003;711-718.
30. Ranganath S., Ouyang W., Bhattarcharya D.et al. GATA-3-dependent enhancer activity in IL-4 gene regulation. J. Immunol. 161:1998;3822-3826.
31. Ory D.S., Neugeboren B.A., Mulligan R.C. A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes. Proc. Natl. Acad. Sci. USA. 93:1996;11400-11406.
32. Runyon K., Lee K., Zuberek K.et al. The combination of chemotherapy and systemic immunotherapy with soluble B7-immunoglobulin G leads to cure of murine leukemia and lymphoma and demonstration of tumor-specific memory responses. Blood. 97:2001;2420-2426.
33. Sperling A.I., Bluestone J.A. ICOS costimulation: it's not just for TH2 cells anymore. Nat. Immunol. 2:2001;573-574.
34. Ozkaynak E., Gao W., Shemmeri N.et al. Importance of ICOS-B7RP-1 costimulation in acute and chronic allograft rejection. Nat. Immunol. 2:2001;591-596.
35. Dunussi-Joannopoulos K., Weinstein H.J., Nickerson P.W.et al. Irradiated B7-1 transduced primary acute myelogenous leukemia (AML) cells can be used as therapeutic vaccines in murine AML. Blood. 87:1996;2938-2946.
36. Townsend S.E., Su F.W., Atherton J.M.et al. Specificity and longevity of antitumor immune responses induced by B7-transfected tumors. Cancer Res. 54:1994;6477-6483.
37. Ara G., Baher A., Storm N.et al. Potent activity of soluble B7RP-1-Fc in therapy of murine tumors in syngeneic hosts. Int. J. Cancer. 103:2003;501-507.
38. Dong C., Juedes A.E., Temann U.A.et al. ICOS co-stimulatory receptor is essential for T-cell activation and function. Nature. 409:2001;97-101.
39. Gonzalo J.A., Tian J., Delaney T.et al. ICOS is critical for T helper cell-mediated lung mucosal inflammatory responses. Nat. Immunol. 2:2001;597-604.
40. Ratliff T.L., Kadmon D., Shapiro A.et al. Inhibition of mouse bladder tumor proliferation by murine interferon-gamma and its synergism with interferon-beta. Cancer Res. 44:1984;4377-4381.
41. Wang B., Xiong Q., Shi Q.et al. Genetic disruption of host interferon-gamma drastically enhances the metastasis of pancreatic adenocarcinoma through impaired expression of inducible nitric oxide synthase. Oncogene. 20:2001;6930-6937.
42. Nakajima C., Uekusa Y., Iwasaki M.et al. A role of interferon-gamma (IFN-gamma) in tumor immunity: T cells with the capacity to reject tumor cells are generated but fail to migrate to tumor sites in IFN-gamma-deficient mice. Cancer Res. 61:2001;3399-3405.